journal article·2024-12-24Open access

Utilizing nanomaterials for cancer treatment and diagnosis: an overview

Bageesha Mukhopadhyay, Sudhakar Singh, Avtar Singh

Discover Nano· Volume 19· Issue 1

Abstract

Cancer is a deadly disease with complex pathophysiological nature and is the leading cause of death worldwide. Traditional diagnosis methods often detect cancer at a considerably critical stage and the conventional methods of treatment like chemotherapy, radiation therapy, targeted therapy, and immunotherapy have several limitations, multidrug resistance, cytotoxicity, and lack of specificity are a few examples. These pose substantial challenge for effective and favourable cancer treatment. The advent of nanotechnology has revolutionized the face of cancer diagnosis and treatment. Nanoparticles, which have a size range of 1-100 nm, are biocompatible and have special optical, magnetic, and electrical capabilities, less toxic, more stable, exhibit permeability and retention effect, and are used for precise targeting. There are several classes of nanoparticles each having their own sets of unique properties. NPs have played an important role in the drug delivery system, overcoming the multi-drug resistance, reducing the side-effects as seen in conventional therapeutic methods and hence able to solve the limitations of conventional methods of diagnosis and treatment. This review discusses the four major classes of nanoparticles (Lipid based NPs, Carbon NPs and Metallic NPs and Polymeric NPs): their discovery and introduction in medical field, unique properties and characteristics, advantages and disadvantages, sub-categories and characteristics of these categories, major area of application in Cancer diagnosis and treatment, and latest methodologies where these are used in cancer treatment.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Graphene and Nanomaterials Applications · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.10.3322/caac.21492 ↗
2. The L. GLOBOCAN 2018: counting the toll of cancer. Lancet. 2018;392(10152):985.10.1016/S0140-6736(18)32252-9 ↗
3. Mahapatro A, Singh DK. Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. J Nanobiotechnol. 2011;9:55. https://doi.org/10.1186/1477-3155-9-55.10.1186/1477-3155-9-55 ↗
4. Chan H-K, Ismail S. Side effects of chemotherapy among cancer patients in a Malaysian general hospital: experiences, perceptions and informational needs from clinical pharmacists. Asian Pac J Cancer Prev. 2014;15(13):5305–9. https://doi.org/10.7314/apjcp.2014.15.13.5305.10.7314/apjcp.2014.15.13.5305 ↗
5. Kroemer G, Zitvogel L. The breakthrough of the microbiota. Nat Rev Immunol. 2018;18:87–8. https://doi.org/10.1038/nri.2018.4.10.1038/nri.2018.4 ↗
6. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to efective cancer immunotherapy. Nat Rev Cancer. 2008;8(4):299–308. https://doi.org/10.1038/nrc2355.10.1038/nrc2355 ↗
7. Lacouture M, Sibaud V. Toxic side efects of targeted therapies and immunotherapies afecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol. 2018;19(Suppl 1):31–9. https://doi.org/10.1007/s40257-018-0384-3.10.1007/s40257-018-0384-3 ↗
8. Dadwal A, Baldi A, Narang RK. Nanoparticles as carriers for drug delivery in cancer. Artif Cells Nanomed Biotechnol. 2018;46(sup2):295–305. https://doi.org/10.1080/21691401.2018.1457039.10.1080/21691401.2018.1457039 ↗
9. Elsabahy M, Wooley KL. Design of polymeric nanoparticles for biomedical delivery applications. Chem Soc Rev. 2012;41(7):2545–61.10.1039/c2cs15327k ↗
10. Bellocq NC, Pun SH, Jensen GS, Davis ME. Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconjug Chem. 2003;14(6):1122–32.10.1021/bc034125f ↗
11. Le Broc-Ryckewaert D, Carpentier R, Lipka E, Daher S, Vaccher C, Betbeder D, Furman C. Development of innovative paclitaxel-loaded small PLGA nanoparticles: study of their antiproliferative activity and their molecular interactions on prostatic cancer cells. Int J Pharm. 2013;454(2):712–9.10.1016/j.ijpharm.2013.05.018 ↗
12. Dayem AA, Hossain M, Lee S, Kim K, Saha S, Yang G-M, Choi H, Cho S-G. The role of reactive oxygen species (ROS) in the biological activities of metallic nanoparticles. Int J Mol Sci. 2017;18(1):120. https://doi.org/10.3390/ijms18010120.10.3390/ijms18010120 ↗
13. Abedin MR, Powers K, Aiardo R, Barua D, Barua S. Antibody-drug nanoparticle induces synergistic treatment efcacies in HER2 positive breast cancer cells. Sci Rep. 2021;11(1):7347.10.1038/s41598-021-86762-6 ↗
14. Bao S, Zheng H, Ye J, Huang H, Zhou B, Yao Q, Lin G, Zhang H, Kou L, Chen R. Dual targeting EGFR and STAT3 with Erlotinib and Alantolactone co-loaded PLGA nanoparticles for pancreatic cancer treatment. Front Pharmacol. 2021;12: 625084.10.3389/fphar.2021.625084 ↗
15. Park SJ. Protein-Nanoparticle Interaction: Corona Formation and Conformational Changes in Proteins on Nanoparticles. Int J Nanomedicine. 2020;15:5783–802. https://doi.org/10.2147/IJN.S254808.10.2147/IJN.S254808 ↗
16. Singh N, Joshi A, Toor AP, Verma G. Drug delivery: advancements and challenges. In: Andronescu E, Grumezescu A, editors. Nanostructures for drug delivery. Amsterdam: Elsevier; 2017. p. 865–86.10.1016/B978-0-323-46143-6.00027-0 ↗
17. Kang EB, Lee JE, Mazrad ZAI, In I, Jeong JH, Park SY. pH-Responsible fuorescent carbon nanoparticles for tumor selective theranostics via pH-turn on/of fuorescence and photothermal efect in vivo and in vitro. Nanoscale. 2018;10(5):2512–23.10.1039/C7NR07900A ↗
18. Subhan MA, Torchilin VP. Efcient nanocarriers of siRNA therapeutics for cancer treatment. Transl Res. 2019;214:62–91.10.1016/j.trsl.2019.07.006 ↗
19. Jin J, Zhao Q. Engineering nanoparticles to reprogram radiotherapy and immunotherapy: recent advances and future challenges. J Nanobiotech. 2020. https://doi.org/10.1186/s12951-020-00629-y.10.1186/s12951-020-00629-y ↗
20. Bartlett DW, Davis ME. Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res. 2006;34(1):322–33.10.1093/nar/gkj439 ↗
21. Tang C, Edelstein J, Mikitsh JL, Xiao E, Hemphill AH 2nd, Pagels R, Chacko AM, Prud’homme R. Biodistribution and fate of core-labeled (125)I polymeric nanocarriers prepared by Flash NanoPrecipitation (FNP). J Mater Chem B. 2016;4(14):2428–34.10.1039/C5TB02172C ↗
22. Peltek OO, Muslimov AR, Zyuzin MV, Timin AS. Current outlook on radionuclide delivery systems: from design consideration to translation into clinics. J Nanobiotechnol. 2019;17(1):90.10.1186/s12951-019-0524-9 ↗
23. https://www.azonano.com/news.aspx?newsID=38833
24. Zhou Y, Peng Z, Seven ES, Leblanc RM. Crossing the blood-brain barrier with nanoparticles. J Control Release. 2018;270:290–303.10.1016/j.jconrel.2017.12.015 ↗
25. Nieto C, Vega MA, Martín Del Valle EM. Trastuzumab: more than a guide in HER2-positive cancer nanomedicine. Nanomaterials (Basel). 2020;10(9):1674.10.3390/nano10091674 ↗
26. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013;200(4):373–83.10.1083/jcb.201211138 ↗
27. Cormode DP, Naha PC, Fayad ZA. Nanoparticle contrast agents for computed tomography: a focus on micelles. Contrast Media Mol Imaging. 2014;9:37–52.10.1002/cmmi.1551 ↗
28. Ozpolat B, Sood AK, Lopez-Berestein G. Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev. 2014;66:110–6.10.1016/j.addr.2013.12.008 ↗
29. https://www.slideshare.net/SachinMali2/sachin-mali
30. Jenning V, Lippacher A, Gohla S. Medium scale production of solid lipid nanoparticles (SLN) by high pressure homogenization. J Microencapsul. 2002;19:1e10.10.1080/713817583 ↗
31. Dumay E, Chevalier-Lucia D, Picart-Palmade L, Benzaria A, Gracia-Julia A, Blayo C. Technological aspects and potential applications of (ultra) high-pressure homogenisation. Trends Food Sci Technol. 2013;31:13e26.10.1016/j.tifs.2012.03.005 ↗
32. Kasongo KW, Muller RH, Walker RB. The use of hot and cold high-pressure homogenization to enhance the loading capacity and encapsulation efficiency of nanostructured lipid carriers for the hydrophilic antiretroviral drug, didanosine for potential administration to paediatric patients. Pharm Dev Technol. 2012;17:353e62.10.3109/10837450.2010.542163 ↗
33. Souto EB, Wissing SA, Barbosa CM, Müller RH. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm. 2004;278(1):71–7.10.1016/j.ijpharm.2004.02.032 ↗
34. Pardeike J, Hommoss A, Muller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm. 2009;366(1–2):170–84.10.1016/j.ijpharm.2008.10.003 ↗
35. Shah RM, Malherbe F, Eldridge D, Palombo EA, Harding IH. Physicochemical characterization of solid lipid nanoparticles (SLNs) prepared by a novel microemulsion technique. J Colloid Interface Sci. 2014;428:286–94.10.1016/j.jcis.2014.04.057 ↗
36. Liu D, Jiang S, Shen H, Qin S, Liu J, Zhang Q, Li R, Xu Q. Diclofenac sodium-loaded solid lipid nanoparticles prepared by emulsion/solvent evaporation method. J Nanopart Res. 2011;13:2375e86.10.1007/s11051-010-9998-y ↗
37. Jaiswal J, Gupta SK, Kreuter J. Preparation of biodegradable cyclosporine nanoparticles by high-pressure emulsification-solvent evaporation process. J Control Release. 2004;96:169e78.10.1016/j.jconrel.2004.01.017 ↗
38. Ekambaram P, Sathali AAH, Priyanka K. Solid lipid nanoparticles: a review. Sci Rev Chem Commun. 2012;2:384.
39. Garud A, Singh D, Garud N. Solid lipid nanoparticles (SLN): method, characterization and applications. Int Curr Pharm J. 2012. https://doi.org/10.3329/icpj.v1i11.12065.10.3329/icpj.v1i11.12065 ↗
40. Charcosset C, El-Harati A, Fessi H. Preparation of solid lipid nanoparticles using a membrane contactor. J Control Release. 2005;108:112e20.10.1016/j.jconrel.2005.07.023 ↗
41. Ahmed El-Harati A, Charcosset C, Fessi H. Influence of the formulation for solid lipid nanoparticles prepared with a membrane contactor. Pharm Dev Technol. 2006;11:153e7.10.1080/10837450600561182 ↗
42. Chattopadhyay P, Shekunov BY, Yim D, Cipolla D, Boyd B, Farr S. Production of solid lipid nanoparticle suspensions using supercritical fluid extraction of emulsions (SFEE) for pulmonary delivery using the AERx system. Adv Drug Deliv Rev. 2007;59:444e53.10.1016/j.addr.2007.04.010 ↗
43. Chen Y, Jin R, Zhou Y, Zeng J, Zhang H, Feng Q. Preparation of solid lipid nanoparticles loaded with Xionggui powder-supercritical carbon dioxide fluid extraction and their evaluation in vitro release Zhongguo Zhong Yao Za Zhi China. J Chin Materia Med. 2006;31:376e9.
44. Wang T, Hu Q, Zhou M, Xue J, Luo Y. Preparation of ultra-fine powders from polysaccharide-coated solid lipid nanoparticles and nanostructured lipid carriers by innovative nano spray drying technology. Int J Pharm. 2016;511:219e22.10.1016/j.ijpharm.2016.07.005 ↗
45. Chen C, Fan T, Jin Y, Zhou Z, Yang Y, Zhu X, Zhang Z-R, Zhang Q, Huang Y. Orally delivered salmon calcitonin-loaded solid lipid nanoparticles prepared by micellee double emulsion method via the combined use of different solid lipids. Nanomedicine. 2013;8:1085e100.10.2217/nnm.12.141 ↗
46. Patidar A, Thakur DS, Kumar P, Verma J. A review on novel lipid based nanocarriers. Int J Pharm Pharm Sci. 2010;2:30e5.
47. MuEller RH, der MaE K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug deliveryea review of the state of the art. Eur J Pharm Biopharm. 2000;50:161e77.
48. Üner M. Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems. Pharmazie. 2006;61:375–86.
49. Danaei M, Dehghankhold M, Ataei S, HasanzadehDavarani F, Javanmard R, Dokhani A, et al. Impact of particle size and polydispersity index on the clinical applications of lipidicnanocarrier systems. Pharmaceutics. 2018;10:57. https://doi.org/10.3390/pharmaceutics10020057.10.3390/pharmaceutics10020057 ↗
50. Tamjidi F, Shahedi M, Varshosaz J, Nasirpour A. Nanostructured lipid carriers (NLC): a potential delivery system for bioactive food molecules. Innov Food Sci Emerg Technol. 2013;19:29–43. https://doi.org/10.1016/j.ifset.2013.03.002.10.1016/j.ifset.2013.03.002 ↗
51. Gordillo-Galeano A, Mora-Huertas CE. Solid lipid nanoparticles and nanostructured lipid carriers: a review emphasizing on particle structure and drug release. Eur J Pharm Biopharm. 2018;133:285–308. https://doi.org/10.1016/j.ejpb.2018.10.017.10.1016/j.ejpb.2018.10.017 ↗
52. Kovacevic A, Savic S, Vuleta G, Mueller RH, Keck CM. Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): effects on size, physical stability and particle matrix structure. Int J Pharm. 2011;406:163–72. https://doi.org/10.1016/j.ijpharm.2010.12.036.10.1016/j.ijpharm.2010.12.036 ↗
53. Shah R, Eldridge D, Palombo E, Harding I. Optimisation and stability assessment of solid lipid nanoparticles using particle size and zeta potential. J Phys Sci. 2014;25:59–75. https://doi.org/10.1007/978-3-319-10711-0_5.10.1007/978-3-319-10711-0_5 ↗
54. Daneshmand S, Golmohammadzadeh S, Jaafari MR, Movaffagh J, Rezaee M, Sahebkar A, et al. Encapsulation challenges, the substantial issue in solid lipid nanoparticles characterization. J Cell Biochem. 2018;119:4251–64. https://doi.org/10.1002/jcb.26617.10.1002/jcb.26617 ↗
55. Attama AA, Reichl S, Müller-Goymann CC. Diclofenac sodium delivery to the eye: In vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct. Int J Pharm. 2008;355:307–13. https://doi.org/10.1016/j.ijpharm.2007.12.007.10.1016/j.ijpharm.2007.12.007 ↗
56. Awasthi R, Bhushan B, Kulkarni GT. Concepts of nanotechnology in nanomedicine: from discovery to applications. In: Dua K, Haghi M, Wadhwa R, Hansbro PM, editors. Targeting Chronic Inflammatory Lung Diseases Using Advanced Drug Delivery Systems. San Diego: Academic Press; 2020.
57. Yingchoncharoen P, Kalinowski DS, Richardson DR. Lipid-based drug delivery systems in cancer therapy: what is available and what is yet to come. Pharmacol Rev. 2016;68:701–87.10.1124/pr.115.012070 ↗
58. Amarnath S, Sharma US. Liposomes in drug delivery: progress and limitations. Int J Pharm. 1997;154:123–40. https://doi.org/10.1016/S0378-5173(97)00135-X.10.1016/S0378-5173(97)00135-X ↗
59. Johnston MJ, Semple SC, Klimuk SK, Ansell S, Maurer N, Cullis PR. Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin. Biochim Biophys Acta. 2007;1768:1121–7. https://doi.org/10.1016/j.bbamem.2007.01.019.10.1016/j.bbamem.2007.01.019 ↗
60. Tenchov R, Bird R, Curtze AE, Zhou Q. Lipid nanoparticles─from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. ACS Nano. 2021;15(11):16982–7015. https://doi.org/10.1021/acsnano.1c04996.10.1021/acsnano.1c04996 ↗
61. Batist G, Gelmon KA, Chi KN, Miller WH Jr, Chia SK, Mayer LD, Swenson CE, Janoff AS, Louie AC. Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin Cancer Res. 2009;15(2):692–700.10.1158/1078-0432.CCR-08-0515 ↗
62. Zhang H, Li RY, Lu X, Mou ZZ, Lin GM. Docetaxel-loaded liposomes: preparation, pH sensitivity, pharmacokinetics, and tissue distribution. J Zhejiang Univ Sci B. 2012;13(12):981–9.10.1631/jzus.B1200098 ↗
63. Yao Y, Su Z, Liang Y, Zhang N. pH-Sensitive carboxymethyl chitosan-modified cationic liposomes for sorafenib and siRNA co-delivery. Int J Nanomed. 2015;10:6185–97.
64. Lee Y, Thompson DH. Stimuli-responsive liposomes for drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017;9(5):e1450.10.1002/wnan.1450 ↗
65. Joshi M, Patravale V. Nanostructured lipid carrier (NLC) based gel of celecoxib. Int J Pharm. 2008;346:124–32. https://doi.org/10.1016/j.ijpharm.2007.05.060.10.1016/j.ijpharm.2007.05.060 ↗
66. Singh K, Arora N, Garg T. Superbug: antimicrobial resistance due to NDM-1. Int J Inst Pharm Life Sci. 2012;2:58–66.
67. Dong Z, Xie S, Zhu L, Wang Y, Wang X, Zhou W. Preparation and in vitro, in vivo evaluations of norfloxacin-loaded solid-lipid nanoparticles for oral delivery. Drug Deliv. 2011;18:441–50. https://doi.org/10.3109/10717544.2011.577109.10.3109/10717544.2011.577109 ↗
68. Goyal G, Garg T, Rath G, Goyal AK. Current nanotechnological strategies for an effective delivery of drugs in treatment of periodontal disease. Crit Rev Ther Drug Carrier Syst. 2014;31:89–119. https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2014008117.10.1615/CritRevTherDrugCarrierSyst.2014008117 ↗
69. Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech. 2011;12(1):62–76.10.1208/s12249-010-9563-0 ↗
70. Sunil K, Harish D. Structural composition of solid lipid nanoparticles for invasive and noninvasive drug delivery. Curr Nanomater. 2017. https://doi.org/10.2174/2405461503666180413160954.10.2174/2405461503666180413160954 ↗
71. Galal A-SMH, Abhishek V, Yash C, Pallavi S, Preeti P, Dilpreet S. , Solid lipid nanoparticles (SLNs): advancements in modification strategies toward drug delivery vehicle. Phar Nanotechnol. 2023. https://doi.org/10.2174/2211738511666221026163303.10.2174/2211738511666221026163303 ↗
72. Obeid MA, Tate RJ, Mullen AB, Ferro VA. Lipid-Based Nanoparticles for Cancer Treatment. Amsterdam: Elsevier Inc.; 2018.10.1016/B978-0-12-813687-4.00008-6 ↗
73. Neerupma D, Rajendra A, Bhupesh S, Harsha K, Kulkarni GT. Lipid nanoparticles as carriers for bioactive delivery. Front Chem. 2021. https://doi.org/10.3389/fchem.2021.580118.10.3389/fchem.2021.580118 ↗
74. Fahmy UA. Augmentation of fluvastatin cytotoxicity against prostate carcinoma PC3 cell line utilizing alpha lipoic-ellagic acid nanostructured lipid carrier formula. AAPS PharmSciTech. 2018;19:3454–61.10.1208/s12249-018-1199-5 ↗
75. Rizwanullah Md, Ahmad MZ, Garg A, Ahmad J. Advancement in design of nanostructured lipid carriers for cancer targeting and theranostic application. Biochimica et Biophysica Acta (BBA)—general subjects. 2021;1865(9):129936. https://doi.org/10.1016/j.bbagen.2021.129936.10.1016/j.bbagen.2021.129936 ↗
76. Ou L, Song B, Liang H, Liu J, Feng X, Deng B, Sun T, Shao L. Toxicity of graphene-family nanoparticles: a general review of the origins and mechanisms. Part Fibre Toxicol. 2016;13(1):57.10.1186/s12989-016-0168-y ↗
77. Krishna KV, Ménard-Moyon C, Verma S, Bianco A. Graphene-based nanomaterials for nanobiotechnology and biomedical applications. Nanomedicine (Lond). 2013;8(10):1669–88.10.2217/nnm.13.140 ↗
78. Liu J, Dong J, Zhang T, Peng Q. Graphene-based nanomaterials and their potentials in advanced drug delivery and cancer therapy. J Control Release. 2018;286:64–73.10.1016/j.jconrel.2018.07.034 ↗
79. Geim AK, Novoselov KS. The rise of graphene. Nat Mater. 2007;6(3):183–91.10.1038/nmat1849 ↗
80. Verde V, Longo A, Cucci LM, Sanflippo V, Magri A, Satriano C, Anfuso CD, Lupo G, La Mendola D. Anti-angiogenic and anti-proliferative graphene oxide nanosheets for tumor cell therapy. Int J Mol Sci. 2020;21(15):5571.10.3390/ijms21155571 ↗
81. Gao W. The chemistry of graphene oxide. In: Gao W, editor. Graphene oxide. Cham: Springer; 2015. p. 61–95.10.1007/978-3-319-15500-5_3 ↗
82. Balandin AA, Ghosh S, Bao W, Calizo I, Teweldebrhan D, Miao F, Lau CN. Superior thermal conductivity of single-layer graphene. Nano Lett. 2008;8(3):902–7.10.1021/nl0731872 ↗
83. Kuilla T, Bhadra S, Yao D, Kim NH, Bose S, Lee JH. Recent advances in graphene based polymer composites. Prog Polym Sci. 2010;35(11):1350–75.10.1016/j.progpolymsci.2010.07.005 ↗
84. Ema M, Gamo M, Honda K. A review of toxicity studies on graphenebased nanomaterials in laboratory animals. Regul Toxicol Pharmacol. 2017;85:7–24.10.1016/j.yrtph.2017.01.011 ↗
85. Li H, Zhao G, Zhang H. Recent progress of cement-based materials modified by graphene and its derivatives. Materials. 2023;16:3783. https://doi.org/10.3390/ma16103783.10.3390/ma16103783 ↗
86. Hummers WS, Offeman RE. Preparation of graphitic oxide. J Am Chem Soc. 1958;80(6):1339–439.10.1021/ja01539a017 ↗
87. Hernandez Y, Nicolosi V, Lotya M, Blighe FM, Sun Z, De S, Coleman JN. High-yield production of graphene by liquid-phase exfoliation of graphite. Nat Nanotechnol. 2008;3(9):563–8.10.1038/nnano.2008.215 ↗
88. Novoselov KS, Geim AK, Morozov SV, Jiang D, Zhang Y, Dubonos SV, Firsov AA. Electric field effect in atomically thin carbon films. Science. 2004;306(5696):666–9.10.1126/science.1102896 ↗
89. Zhao J, Pei S, Ren W, Gao L, Cheng HM. Efficient preparation of large-area graphene oxide sheets for transparent conductive films. ACS Nano. 2010;4(9):5245–52.10.1021/nn1015506 ↗
90. Parvez K, Wu Z-S, Li R, Liu X, Graf R, Feng X, Mullen K. Exfoliation of graphite into graphene in aqueous solutions of inorganic salts. J Am Chem Soc. 2014;136(16):6083–91.10.1021/ja5017156 ↗
91. Cote LJ, Kim F, Huang J. Langmuir-Blodgett assembly of graphite oxide single layers. J Am Chem Soc. 2009;131(3):1043–9.10.1021/ja806262m ↗
92. Li X, Cai W, An J, Kim S, Nah J, Yang D, Ruoff RS. Large-area synthesis of high-quality and uniform graphene films on copper foils. Science. 2009;324(5932):1312–4.10.1126/science.1171245 ↗
93. Tang L, Ji R, Li X, Teng KS, Lau SP. Size-dependent structural and optical characteristics of glucose-derived graphene quantum dots. Part Part Syst Charact. 2012;29(8):759–62.
94. Zhou M, Zhai Y, Dong S. Electrochemical sensing and biosensing platform based on chemically reduced graphene oxide. Anal Chem. 2011;81(14):5603–13.10.1021/ac900136z ↗
95. Li D, Kaner RB. Graphene-based materials. Science. 2008;320(5880):1170–1.10.1126/science.1158180 ↗
96. Gomez-Navarro C, Weitz RT, Bittner AM, Scolari M, Mews A, Burghard M, Kern K. Electronic transport properties of individual chemically reduced graphene oxide sheets. Nano Lett. 2010;7(11):3499–503.10.1021/nl072090c ↗
97. Rao CNR, Sood AK, Subrahmanyam KS, Govindaraj A. Graphene: the new two-dimensional nanomaterial. Angew Chem Int Ed. 2009;48(42):7752–77.10.1002/anie.200901678 ↗
98. Zainal-Abidin MH, Hayyan M, Ngoh GC, Wong WF, Looi CY. Potentiating the anti-cancer profile of tamoxifen-loaded graphene using deep eutectic solvents as functionalizing agents. Appl Nanosci. 2020;10:293–304.10.1007/s13204-019-01105-2 ↗
99. Zainal-Abidin MH, Hayyan M, Ngoh GC, Wong WF. Doxorubicin loading on functional graphene as a promising nanocarrier using ternary deep eutectic solvent systems. ACS Omega. 2020;5:1656–68.10.1021/acsomega.9b03709 ↗
100. Lucherelli MA, Yu Y, Reina G, Abellán G, Miyako E, Bianco A. Rational chemical multifunctionalization of graphene interface enhances targeted cancer therapy. Angew Chemie. 2020;132:14138–43.10.1002/ange.201916112 ↗